BiotechTube

Conivaptan

ApprovedTerminated
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Hyponatremia

Conditions

Hyponatremia

Trial Timeline

Aug 1, 2008 → Feb 1, 2010

NCT ID
NCT00727090

About Conivaptan

Conivaptan is a approved stage product being developed by Astellas Pharma for Hyponatremia. The current trial status is terminated. This product is registered under clinical trial identifier NCT00727090. Target conditions include Hyponatremia.

What happened to similar drugs?

0 of 7 similar drugs in Hyponatremia were approved

Approved (0) Terminated (3) Active (4)
🔄YM087Astellas PharmaPhase 3
❌ConivaptanAstellas PharmaPhase 3
❌Satavaptan + placeboSanofiPhase 3
🔄lixivaptan + PlaceboBiogenPhase 3
❌LixivaptanBiogenPhase 3
🔄lixivaptan + placeboBiogenPhase 3
🔄Lixivaptan + PlaceboBiogenPhase 3

Hype Score Breakdown

Clinical
20
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (3)

NCT IDPhaseStatus
NCT00806910ApprovedWithdrawn
NCT00727090ApprovedTerminated
NCT00684164Phase 3Withdrawn

Competing Products

9 competing products in Hyponatremia

See all competitors
ProductCompanyStageHype Score
YM087Astellas PharmaPhase 3
40
ConivaptanAstellas PharmaPhase 3
32
Tolvaptan + PlaceboJiangsu Hengrui MedicinePhase 2/3
34
Satavaptan + placeboSanofiPhase 3
32
lixivaptan + PlaceboBiogenPhase 3
37
LixivaptanBiogenPhase 3
29
lixivaptan + placeboBiogenPhase 3
37
Lixivaptan + PlaceboBiogenPhase 3
37
PEG-SD + PEG-ELSBausch HealthPre-clinical
20